BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 28945609)

  • 21. The genetic landscape of endometrial clear cell carcinomas.
    DeLair DF; Burke KA; Selenica P; Lim RS; Scott SN; Middha S; Mohanty AS; Cheng DT; Berger MF; Soslow RA; Weigelt B
    J Pathol; 2017 Oct; 243(2):230-241. PubMed ID: 28718916
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MDM2 and p53 protein expression in the histologic subtypes of endometrial carcinoma.
    Ambros RA; Sheehan CE; Kallakury BV; Ross JS; Malfetano J; Paunovich E; Figge J
    Mod Pathol; 1996 Dec; 9(12):1165-9. PubMed ID: 8972476
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunohistochemical Profiling of Endometrial Serous Carcinoma.
    Chen W; Husain A; Nelson GS; Rambau PF; Liu S; Lee CH; Lee S; Duggan MA; Köbel M
    Int J Gynecol Pathol; 2017 Mar; 36(2):128-139. PubMed ID: 27167671
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Correlative Assessment of p53 Immunostaining Patterns and TP53 Mutation Status by Next-Generation Sequencing in High-Grade Endometrial Carcinomas.
    Matsumoto N; Manrai P; Rottmann D; Wu X; Assem H; Hui P; Buza N
    Int J Gynecol Pathol; 2023 Nov; 42(6):567-575. PubMed ID: 36730675
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinicopathologic and Genomic Analysis of
    Momeni-Boroujeni A; Dahoud W; Vanderbilt CM; Chiang S; Murali R; Rios-Doria EV; Alektiar KM; Aghajanian C; Abu-Rustum NR; Ladanyi M; Ellenson LH; Weigelt B; Soslow RA
    Clin Cancer Res; 2021 May; 27(9):2613-2623. PubMed ID: 33602681
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High concordance of molecular tumor alterations between pre-operative curettage and hysterectomy specimens in patients with endometrial carcinoma.
    Stelloo E; Nout RA; Naves LC; Ter Haar NT; Creutzberg CL; Smit VT; Bosse T
    Gynecol Oncol; 2014 May; 133(2):197-204. PubMed ID: 24556061
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High-grade Endometrial Carcinomas: Morphologic and Immunohistochemical Features, Diagnostic Challenges and Recommendations.
    Murali R; Davidson B; Fadare O; Carlson JA; Crum CP; Gilks CB; Irving JA; Malpica A; Matias-Guiu X; McCluggage WG; Mittal K; Oliva E; Parkash V; Rutgers JKL; Staats PN; Stewart CJR; Tornos C; Soslow RA
    Int J Gynecol Pathol; 2019 Jan; 38 Suppl 1(Iss 1 Suppl 1):S40-S63. PubMed ID: 30550483
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Interpretation of P53 Immunohistochemistry in Endometrial Carcinomas: Toward Increased Reproducibility.
    Köbel M; Ronnett BM; Singh N; Soslow RA; Gilks CB; McCluggage WG
    Int J Gynecol Pathol; 2019 Jan; 38 Suppl 1(Iss 1 Suppl 1):S123-S131. PubMed ID: 29517499
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Confirmation of ProMisE: A simple, genomics-based clinical classifier for endometrial cancer.
    Talhouk A; McConechy MK; Leung S; Yang W; Lum A; Senz J; Boyd N; Pike J; Anglesio M; Kwon JS; Karnezis AN; Huntsman DG; Gilks CB; McAlpine JN
    Cancer; 2017 Mar; 123(5):802-813. PubMed ID: 28061006
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Metachronous serous endometrial intraepithelial carcinoma and serous peritoneal carcinoma: analysis of probable independent lesions.
    Furuya M; Sato T; Tanaka R; Yamamoto M; Yokota NR; Miyagi E
    Diagn Pathol; 2016 Nov; 11(1):130. PubMed ID: 27842566
    [TBL] [Abstract][Full Text] [Related]  

  • 31. TP53 Mutational Spectrum in Endometrioid and Serous Endometrial Cancers.
    Schultheis AM; Martelotto LG; De Filippo MR; Piscuglio S; Ng CK; Hussein YR; Reis-Filho JS; Soslow RA; Weigelt B
    Int J Gynecol Pathol; 2016 Jul; 35(4):289-300. PubMed ID: 26556035
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Equivalent Survival of p53 Mutated Endometrial Endometrioid Carcinoma Grade 3 and Endometrial Serous Carcinoma.
    Brett MA; Atenafu EG; Singh N; Ghatage P; Clarke BA; Nelson GS; Bernardini MQ; Köbel M
    Int J Gynecol Pathol; 2021 Mar; 40(2):116-123. PubMed ID: 32265358
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Minimal uterine serous carcinoma with extrauterine tumor of identical morphology: an immunohistochemical study of 13 cases.
    Yan Z; Hui P
    Appl Immunohistochem Mol Morphol; 2010 Jan; 18(1):75-9. PubMed ID: 19956063
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Diagnostic Variation in p53 Usage for Endometrial Carcinoma Diagnosis: Implications for Molecular Subtyping.
    Baniak N; Gilks CB; DeCoteau J; Kinloch M
    Int J Gynecol Pathol; 2020 Nov; 39(6):514-521. PubMed ID: 31569187
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A dualistic model for endometrial carcinogenesis based on immunohistochemical and molecular genetic analyses.
    Lax SF; Kurman RJ
    Verh Dtsch Ges Pathol; 1997; 81():228-32. PubMed ID: 9474874
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Undifferentiated Carcinoma of the Endometrium: An Expanded Immunohistochemical Analysis Including PAX-8 and Basal-Like Carcinoma Surrogate Markers.
    Ramalingam P; Masand RP; Euscher ED; Malpica A
    Int J Gynecol Pathol; 2016 Sep; 35(5):410-8. PubMed ID: 26598976
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic significance and diagnostic value of PTEN and p53 expression in endometrial carcinoma. A retrospective clinicopathological and immunohistochemical study.
    Daniilidou K; Frangou-Plemenou M; Grammatikakis J; Grigoriou O; Vitoratos N; Kondi-Pafiti A
    J BUON; 2013; 18(1):195-201. PubMed ID: 23613406
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Coexisting intraepithelial serous carcinomas of the endometrium and fallopian tube: frequency and potential significance.
    Jarboe EA; Miron A; Carlson JW; Hirsch MS; Kindelberger D; Mutter GL; Crum CP; Nucci MR
    Int J Gynecol Pathol; 2009 Jul; 28(4):308-15. PubMed ID: 19483636
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeted sequencing with a customized panel to assess histological typing in endometrial carcinoma.
    Cuevas D; Valls J; Gatius S; Roman-Canal B; Estaran E; Dorca E; Santacana M; Vaquero M; Eritja N; Velasco A; Matias-Guiu X
    Virchows Arch; 2019 May; 474(5):585-598. PubMed ID: 30710169
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunohistochemical staining patterns of p53 can serve as a surrogate marker for TP53 mutations in ovarian carcinoma: an immunohistochemical and nucleotide sequencing analysis.
    Yemelyanova A; Vang R; Kshirsagar M; Lu D; Marks MA; Shih IeM; Kurman RJ
    Mod Pathol; 2011 Sep; 24(9):1248-53. PubMed ID: 21552211
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.